MIGRATION OF OZURDEX IMPLANT INTO THE ANTERIOR CHAMBER
Authors:
- 1 January 2012
- journal article
- case report
- Published by Wolters Kluwer Health in RETINAL Cases & Brief Reports
- Vol. 6 (3) , 269-270
Abstract
Purpose: The purpose of this study was to report a novel complication of Ozurdex implantation in which the implant migrates into the anterior chamber and to describe the subsequent clinical course. Methods: After identification of the implant in the inferior anterior chamber, clinical photographs were obtained. Baseline measurements of vision, corneal thickness, and corneal cell counts were likewise collected. The patent was followed for clinical sequelae. Results: After 4 months, the implant was clearly observed to be degrading. Repeat corneal pachymetry, slit-lamp examination, and visual acuity were stable. Discussion: Patients with a patent peripheral iridotomy who received Ozurdex intravitreal implants are at risk for migration of the implant into the anterior chamber. However, the implant itself appears to be benign, causing no detrimental effects to the corneal endothelium.Keywords
This publication has 5 references indexed in Scilit:
- Randomized, Sham-Controlled Trial of Dexamethasone Intravitreal Implant in Patients with Macular Edema Due to Retinal Vein OcclusionOphthalmology, 2010
- Corneal complications of glaucoma surgeryCurrent Opinion in Ophthalmology, 2009
- Randomized Controlled Study of an Intravitreous Dexamethasone Drug Delivery System in Patients With Persistent Macular EdemaArchives of Ophthalmology (1950), 2007
- Safety and efficacy of a dexamethasone anterior segment drug delivery system in patients after phacoemulsificationJournal of Cataract & Refractive Surgery, 2004
- Randomized clinical trial of a new dexamethasone delivery system (surodex) for treatment of post-cataract surgery inflammation11The authors have no financial interest in this or competing products or in Surodex or Oculex Pharmaceuticals, Inc.Ophthalmology, 1999